Avanir (AVNR) More Than Doubles On NUEDEXTA Approval
Tweet Send to a Friend
Get Alerts AVNR Hot Sheet
Up)
Trade AVNR Now!
Shares of Avanir Pharmaceuticals (Nasdaq: AVNR) are trading up 114 percent to $5.18 in pre-open action Monday following FDA approval for NUEDEXTA as the first treatment for pseudobulbar affect.
pseudobulbar affect, or PBA, occurs secondary to a number of unrelated neurological condition, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.
Avanir expects NUEDEXTA to become available by prescription during the first quarter of 2011.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
pseudobulbar affect, or PBA, occurs secondary to a number of unrelated neurological condition, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.
Avanir expects NUEDEXTA to become available by prescription during the first quarter of 2011.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Medtronic (MDT) Receives CE Mark for Export Advance Catheter
- Ligand Pharmaceuticals (LGND) Agreement with Merck KGaA Unit Terminated
- Oramed Pharma (ORMP) OK'd by FDA for ORMD-0801 IND
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
